Spotlight On... Can Shire make the most of Baxalta's hemophilia meds?; AZ brings new blood into corp comms; Stricter DTC oversight expected in India; and more...

Shire ($SHPG) CEO Flemming Ornskov says his own goals for cost savings, post-merger with Baxalta ($BXLT), are higher than the company's stated $500 million. But analysts are still skeptical of the deal; they're particularly worried about stepped-up competition in hemophilia with new meds hitting the market. More from FiercePharma

> AstraZeneca ($AZN) has some new faces on its global communications team, with Neil Burrows as head of global media relations and Ali Perkins as head of communications for global medicines development. Report

> Indian drugmakers expect stricter curbs on consumer advertising. Though DTC campaigns are technically prohibited, the laws have loopholes, experts say. Report

> Sanofi's ($SNY) Korean unit and LG Life Sciences are locked in a dispute over a co-promotion deal on LG's top diabetes meds. Report

> Antidepressant treatment helps diabetics control their blood sugar, a new study found, potentially spurring more patients with both disorders to seek treatment. Report

And Finally... Kids with Type 1 diabetes are finding comfort in American Girl dolls styled as diabetics. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The U.S. aesthetics business is booming with fillers and fat freezers garnering interest, and spurring marketing campaigns, post-lockdown COVID-19.